Hydrix gains medical and Defence traction as cash becomes the next test

Revenue growth arrives alongside tight liquidity

Hydrix Limited (ASX:HYD) started FY27 with better operating momentum, but not much room for execution risk. September-quarter revenue reached $2.8 million, rising 11.6% from the prior corresponding quarter and 28.1% from the June quarter, while Services contract sales totalled $4.1 million.

The more immediate financial issue is cash. Hydrix ended September with $1.5 million, after $2.5 million of customer receipts and $1.1 million of net operating cash use. On the Appendix 4C calculation, that represented 1.30 quarters of funding, with no unused finance facilities available and $6.0 million of facilities shown as drawn.

The company attributed the cash pressure to delayed customer payments on projects tied to capital raisings or milestone payments, as well as one-off costs linked to its June-quarter capital raise and the move to monthly superannuation payments. Hydrix said it expects delayed receipts to be brought up to date in the December quarter, but it did not provide a firm collection date. Its funding position also depends in part on current trading assumptions and proposed conversions of certain loans to equity, subject to shareholder approval at the 26 November annual meeting.

Singapore contract opens recurring-revenue path

Hydrix Medical recorded its first commercial sale of the Implicity remote cardiac monitoring platform in Asia-Pacific through a multiyear contract worth approximately $0.65 million with Singapore’s National Heart Centre. The sale builds on the Singapore heart centre contract, which was earlier reported as a three-year agreement expected to generate about A$0.625 million depending on patient volumes and implementation.

Hydrix described the hospital as a regional reference customer and said the agreement provides a foundation for further expansion across Australia, Singapore and New Zealand, as well as recurring revenue. Those are commercial possibilities rather than recognised revenue in the quarter, making implementation and subsequent customer uptake important markers for the medical division.

Defence work advances from strategy to delivery

Hydrix Defence delivered the first benchtop integration system under its A$1.2 million development contract with NIOA, ahead of planned December-quarter flight trials. The work involves a Power and Interface Controller for NIOA’s kinetic effector payload under the Australian Sovereign Capability Accelerator’s Mission Syracuse.

The company also evaluated 12 Defence technology development and commercialisation opportunities, with four moving into active technical and market review. That activity extends the Defence IP commercialisation push previously described by Hydrix, but the filing does not attach revenue values or delivery timelines to the four initiatives under review.

Services pipeline must translate into cash

Hydrix said engineering work on the Remedy Robotics programme progressed during the quarter, drawing on its embedded electronics, safety-critical software, systems integration and verification capabilities. The update adds execution progress to the Remedy Robotics contract, previously announced at A$3.4 million with revenue scheduled to be recognised progressively through FY2027.

Management’s stated priorities are to convert contracted projects and the sales pipeline into revenue, improve profitability and develop Australian-owned technology that can produce longer-term income. The next quarter will test whether the operational progress can show up in customer receipts, while the AGM will determine whether proposed debt conversions can ease pressure on the balance sheet.